article thumbnail

STAT+: Documents detail how pharmacy giants Walgreens, CVS, and Walmart failed patients in the opioid epidemic

STAT

In 2011, Walgreens executives were under pressure. Amid a growing addiction crisis, and with the country already awash in prescription painkillers, the federal government was demanding accountability from the pharmacy giant for filling thousands of opioid prescriptions written by doctors in suspiciously large quantities.  

article thumbnail

STAT+: Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more

STAT

regulators in 2011. The FDA still has to make a decision on whether to officially place semaglutide on the lists. Novo has repeatedly argued that compounded products are risky, stressing that they are not approved by the FDA. Eylea can treat eye diseases like macular degeneration, macular edema, and retinopathy, and was first approved by U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

510(k) Modernization 2023

The FDA Law Blog

Lenz, Principal Medical Device Regulation Expert — On September 6, 2023, FDA announced its latest efforts to modernize the 510(k) process, outlining FDA’s latest improvements to strengthen the 510(k) Program and announcing release of three draft guidance documents.

article thumbnail

FDA Flexes its New FDORA Muscles in Withdrawing an Accelerated Approval

The FDA Law Blog

This is the third withdrawal of an accelerated approval FDA has performed, following Avastin in 2011 and Makena in 2023. In contrast , the two previous withdrawals, Makena in 2023 and Avastin in 2011, took 30 months and 11 months, respectively. All in all, the new expedited procedures took about 7 months from proposal to withdrawal.

FDA 57
article thumbnail

New regulatory relief to benefit Europe’s pharma SMEs

European Pharmaceutical Review

This will allow these firms to complete administrative procedures across the Single Market without needing to re-submit documents. The new rules will repeal the 2011 Directive on late payments and will replace it with a Regulation. Boost investments available for SMEs , for example, ensuring that part of the proposed €7.5

article thumbnail

7 Best Metformin Alternatives For Type 2 Diabetes

Druggist

The official guide on type-2 diabetes management: document produced by NICE for healthcare professionals in the UK, which recommends treatment for type-2 diabetes. . Modified-release metformin provide better gastrointestinal tolerability (Jabbour & Ziring, 2011). 2011 Sep;13(9):775-83. Jabbour S, Ziring B (2011).

article thumbnail

Novartis agrees $245m settlement over Exforge generics delay

pharmaphorum

The case revolves around allegations that Novartis made an agreement in 2011 with Par Pharmaceutical when Exforge (valsartan/amlodipine) was nearing the end of its patent life that was designed to keep Par’s generic version of the drug off the market until 30 September, 2014.